1 / 0

BUS6900 IP Strategy and Management NOVARTIS GROUP

BUS6900 IP Strategy and Management NOVARTIS GROUP. Jian Gu Sedem Yener Elias Jaime Porras. Context. About Novartis Company IP Portfolio IP strategy and management Future plan for Novartis Company. About Novartis Company. multinational pharmaceutical company

davina
Download Presentation

BUS6900 IP Strategy and Management NOVARTIS GROUP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BUS6900 IP Strategy and ManagementNOVARTIS GROUP

    JianGu SedemYener Elias Jaime Porras
  2. Context About Novartis Company IP Portfolio IP strategy and management Future plan for Novartis Company
  3. About Novartis Company multinational pharmaceutical company was created in 1996 from the merger of Ciba-Geigy (1860)and Sandoz Laboratories (1886). offers a wide range of healthcare products through their Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions. Is a full member of the European Federation of Pharmaceutical Industries and Associations. It is Swiss company but main local is USA Cambridge. La Jolla, there is Genetic Institute, researching new medicines. In 1998 the company made headlines with its biotechnology licensing agreement with the UC Berkeley Department of Plant and Microbial Biology.
  4. Details CEO :Dr. Daniel Vasella, M.D. Employees : 98,200 Market Cap :107,150,055,000 Auditor :PriceWaterHouse Cooperation A.G. Gross Margin :71.3 M Profit Margin : 38.1 M EBIT Margin :20.9 M Return on Equity :23.9 M Return on Capital :22.9 M Return on Assets : 14.8 M Investment : 6.8 M
  5. Pharmaceuticals Products of Novartis Company (18) Diovan- $5.0 B sales(2007)- Hypertension Gleevec - $3.1 B- for Chronic myeloid leukemia Zometa- $1.3 B (2007)- Cancer complications Sandostatin - $1.0 B (2007) - Acromegaly SandimmunNeoral- $944 M (2007)- Transplantation Femara- $937 M (2007)- Breast cancer Lotrel- $748 M (2007)- Hypertension Voltaren- $747 M (2007)- Inflammation Trileptal- $692 M (2007)- Epilepsy Lescol- $665 M (2007)- cholestrol Exelon- $632 M (2007)- Alzheimer's disease Comtan- $420 M (2007)- Parkinson's disease Tegretol- $413 M (2007)- Epilepsy Lucentis- $393 M (2007)- Age-related macular degeneration Ritalin- $375 M (2007) - ADD Exjade- $357 M (2007) – Iron chelator Tobramycin- $273 M (2007)- Cystic fibrosis Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain.
  6. Major therapeutic areas: autoimmunity/transplantation/ inflammatory disease cardiovascular disease diabetes gastrointestinal disease infectious diseases musculoskeletal disease neuroscience oncology ophthalmology respiratory disease
  7. Novartis IP portfolio!!! involves coordination and quality control of biologics patenting and freedom-to-operate analysis across all disease areas, platforms, and functions within NIBR. is Director of Intellectual Property John T. LiPatents, Head, Biology & Biologics, Novartis Institutes forBiomedical ResearchNovartis In USA
  8. Novartis IP portfolio and It’s Process!!! operates in 140 countries and currently has 75 new treatments in the pipeline More than 12,000 US Granted Patents. Patent Mapping Reports provide specific and detailed insights into patenting activities of specific Fortune 500, NASDAQ and Novartis is in top 100. Is gearing up to break new CSR ground, with a funding proposal for neglected disease research that advantages IP rights to strike a balance between corporate return on investment and the condition of fundamental treatments to penniless developing countries.
  9. Novartis IP portfolio and It’s Process!!! The International Patent Classification (IPC) is a hierarchical system in which the whole area of technology is divided into a range of sections, classes, subclasses and groups. IPC (International Patent Classification ) (US Patent Classification) UPC NAICS (North American Industrial Classification System) (this new, uniform, industry)
  10. Future Planning Novartis is planning release 17 new pharmaceutical products. They are going to spend more then $12M for investment and IP Strategy. Novartis Buys Additional 51.7% Stake in Speedel company. Make e-business partnership: World Online and Novartis plan together to build initially a pan-European portal and an e-commerce platform that will become the first of its kind within the healthcare and wellness arena. 30% Increase In US Supplies Of Fluvirin Influenza Vaccines And Delivery Of 40 Million Doses. will be replaced by two Novartis execs who will oversee development in newly created roles.
  11. Contacts with Novartis General Manager in Turkey :GundemBerkmen Director of Neuroscience BF : Selahattin Saygan Director of Marketing Strategy :Bahadir Pakis Marketing and Sale Manager :AytenPolat
  12. Thank you!!! Any Question?
More Related